Stem Cell Therapy in Los Cabos: A Practical Guide to Treatment at Rehealth

A diagnosis of a neurodegenerative disease changes the questions a family asks. Alongside the standard treatment plan, most people begin looking for anything else that might help, and mesenchymal stem cell therapy is one of the options they encounter most often.
This article explains what mesenchymal stem cells are, what the current research does and does not show for neurodegenerative conditions, who may be considered a candidate, and what the treatment process looks like at Rehealth Regenerative Therapies in Mexico. It is written to help you ask better questions of your own neurologist, not to replace their advice.
One point belongs at the top rather than buried at the bottom. There is no approved mesenchymal stem cell therapy that cures, halts or reverses any neurodegenerative disease anywhere in the world. Research is genuinely active and some early-phase results are encouraging, but the honest position today is that this is an investigational area. Any provider who tells you otherwise is not being straight with you.
Understanding Neurodegenerative Diseases
Neurodegenerative diseases progressively damage nerve cells in the brain, spinal cord or peripheral nervous system. As those cells are lost, symptoms accumulate and typically affect movement, memory, coordination, speech or day-to-day independence.
The conditions most often discussed in this category include:
Parkinson's disease
Alzheimer's disease and other dementias
Multiple sclerosis (MS)
Amyotrophic lateral sclerosis (ALS)
Huntington's disease
These conditions differ enormously from one another in cause, progression and available treatment. Multiple sclerosis, for example, is primarily immune-mediated and has a substantial number of approved disease-modifying drugs. Huntington's disease is caused by a single inherited genetic mutation. Grouping them together is useful for a general overview, but it should not be read to mean a single therapy is equally relevant to all of them. The research base for MSCs is meaningfully stronger in some of these conditions than others.
Standard care remains the foundation of treatment in every one of these diseases. Regenerative medicine is being investigated as a possible addition to that care, not a replacement for it.
What Is Mesenchymal Stem Cell Therapy?
Mesenchymal stem cells, often called mesenchymal stromal cells, are adult cells that can be obtained from sources such as bone marrow, adipose tissue and umbilical cord tissue. They have been studied for several decades, and thousands of clinical trials involving them have been registered worldwide.
An important and frequently misunderstood point: MSCs do not replace lost neurons. They do not turn into brain cells and rebuild damaged circuits. The mechanisms under investigation are indirect, and centre on the signalling molecules these cells release. Researchers are studying whether MSCs may:
Modulate immune activity, which is relevant in conditions with a significant inflammatory component
Reduce local inflammation in nervous tissue
Release growth factors and other trophic signals
Influence the local cellular environment in ways that support surviving cells
[Citation 1 — link a peer-reviewed review of MSC mechanisms in neurological disease.]
These mechanisms are plausible and supported by laboratory and animal work. Translating them into measurable, durable clinical benefit in humans is the part that remains unresolved.
What the Current Research Actually Shows
Rather than list benefits, it is more useful to describe the state of the evidence, because that is what determines whether this is a reasonable option for you.
Safety
Across many early-phase trials, MSC administration has generally been reported as well tolerated, with serious adverse events uncommon. Safety findings are the most consistent part of the evidence base. This is not the same as proof of effectiveness.
[Citation 2 — link a published safety analysis or phase 1/2 trial.]
Effectiveness
This is where the picture is far less settled. Most published studies are small, early-phase, and designed to assess safety and feasibility rather than to prove benefit. Some report improvements in specific measures; others report no significant difference from control. Large, well-controlled trials that would be needed to establish effectiveness have generally not been completed.
[Citation 3 — link a recent phase 1/2 trial in MS, Parkinson's or ALS and summarise its stated conclusion accurately.]
Variation between conditions
The volume and quality of research differs substantially across the conditions listed earlier. There is more clinical trial activity in multiple sclerosis than in Huntington's disease, for example. During your consultation, ask specifically what evidence exists for your diagnosis rather than for neurodegenerative disease as a category.
What this means for you
Individual responses vary, and no specific outcome can be promised. Anyone considering this therapy should understand that they are choosing an investigational option, and should weigh the cost, the travel and the uncertainty against the potential for benefit. That decision belongs to you and your treating physician.
Who May Be Considered a Candidate?
Not everyone who enquires is accepted. Physician evaluation exists precisely to identify who should not proceed. Factors that are generally considered include:
A confirmed diagnosis from a treating neurologist
Medical stability sufficient to travel and tolerate the procedure
Realistic expectations about what the therapy may and may not do
An intention to continue conventional care rather than replace it
Approval following a full medical assessment
Patients are declined when the assessment indicates the therapy is unlikely to be appropriate, when medical risk is too high, or when expectations cannot be reconciled with what the treatment realistically offers. If you are told you qualify before anyone has reviewed your records, treat that as a warning sign at any clinic.
The Treatment Process at Rehealth
Initial medical consultation
The process begins with a detailed review of your medical history, current diagnosis and staging, previous and current treatments, imaging and laboratory reports, current medications, and your treatment goals. Records from your treating neurologist are requested wherever possible.
Personalised treatment planning
If the assessment supports proceeding, physicians build a protocol around your specific condition, health status and history. Cell type, dose and route of administration are clinical decisions made case by case.
Laboratory processing
Rehealth operates its own laboratory rather than outsourcing preparation entirely to third parties, which allows direct oversight of processing conditions, sterility and quality assurance at each stage.
Treatment administration
Therapy is administered under medical supervision using the method determined during planning. Your physician will explain the route, the expected duration and the specific risks that apply to your case before you consent.
Follow-up
Care continues after you return home through scheduled follow-up, progress monitoring and ongoing communication. Ask at the outset how follow-up is handled once you have left Mexico, and what happens if you experience a complication after travelling.
Questions Worth Asking Any Regenerative Medicine Provider
These apply to Rehealth and to every other clinic you evaluate:
What published evidence exists for my specific diagnosis, and can you send me those papers?
What is the source, type and dose of the cells being used?
What is the total cost, and what does it include?
What are the risks, and what is your complication rate?
Who provides follow-up after I return home?
Under what circumstances would you decline to treat me?
A provider confident in their practice will answer all six directly.
Frequently Asked Questions
Can MSC therapy cure a neurodegenerative disease?
No. There is no approved mesenchymal stem cell therapy that cures or reverses any neurodegenerative disease. Research is ongoing and remains largely at an early clinical stage.
Is MSC therapy approved by the FDA?
The FDA has not approved mesenchymal stem cell therapy for any neurodegenerative condition. Treatments offered outside the United States operate under the regulatory framework of the country where the clinic is located.
Should I stop my current medication?
No. Regenerative therapy is considered alongside conventional treatment, never as a substitute for it. Any change to your medication should be made only by your treating neurologist.
How long before any effect might be noticed?
This varies considerably between individuals and conditions, and some patients notice no change. Your physician will discuss what is reasonable to expect in your particular case rather than offering a fixed timeline.
Where are Rehealth's clinics located?
Rehealth operates two clinics in Mexico: one in Cancun in the Zona Hotelera, and one in Los Cabos at Plaza Koral in San Jose del Cabo. Both accept international patients.
How much does treatment cost?
Cost depends on the protocol determined during your consultation. Pricing is discussed openly before any commitment is made.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Mesenchymal stem cell therapy for neurodegenerative diseases is an investigational area of regenerative medicine. It is not an approved treatment for any neurodegenerative condition, individual results vary, and Rehealth does not guarantee any specific outcome. Always consult your treating physician before making decisions about your care.
Book a Consultation
If you would like to understand whether mesenchymal stem cell therapy may be appropriate for your condition, the medical team at Rehealth can review your records and give you a direct answer, including if that answer is no.
Call [phone] to speak with the Rehealth team, or request a consultation online. Clinics in Cancun and Los Cabos, Mexico.